A double-blind, randomized, placebo-controlled, parallel-group, 16 week, multicenter trial evaluating the efficacy and safety of levetiracetam 500 mg tablets in bid [twice daily] administration (daily dose ranging from 1000 mg to 3000 mg), in adults (greater than or equal to 18 years of age) suffering from postherpetic neuralgia
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Levetiracetam (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors UCB Pharma Inc
- 16 Jul 2007 Status changed from in progress to completed.
- 17 Nov 2005 New trial record.